# Study of Aripiprazole in the Treatment of Serious Behavioral Problems in Children and Adolescents With Autistic Disorder (AD)

> **NCT00365859** · PHASE3 · COMPLETED · sponsor: **Otsuka Pharmaceutical Development & Commercialization, Inc.** · enrollment: 330 (actual)

## Conditions studied

- Autistic Disorder
- Behavioral Symptoms

## Interventions

- **DRUG:** Aripiprazole

## Key facts

- **NCT ID:** NCT00365859
- **Lead sponsor:** Otsuka Pharmaceutical Development & Commercialization, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09
- **Primary completion:** 2009-06
- **Final completion:** 2009-06
- **Target enrollment:** 330 (ACTUAL)
- **Last updated:** 2013-12-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00365859

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00365859, "Study of Aripiprazole in the Treatment of Serious Behavioral Problems in Children and Adolescents With Autistic Disorder (AD)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00365859. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*